文献速递肝胆胰外科围术期管理与 ERAS

可切除与交界可切除胰腺癌新辅助治疗及术后首次复发的影像学模式

Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
PubMed 文献 · Surgery · 2020-07-05

本研究纳入306例完成新辅助治疗及手术的局限性胰腺癌患者,中位随访27个月时186例(61%)复发,首次复发以远处转移为主(28%),局部复发仅占9%;

要点

  • 新辅助治疗后手术的胰腺癌患者中,首次复发以远处转移最常见(28%),局部-only复发仅9%。
  • 全部患者中位无进展生存期为24个月,随访27个月时61%出现复发。

核心结论

  • 新辅助治疗及手术后,9%的胰腺癌患者出现局部-only复发,远处转移仍为主要复发模式。
  • 包含新辅助放化疗的治疗顺序可能改善局部疾病控制。

研究设计与样本

  • 回顾性分析306例完成新辅助治疗及手术的局限性胰腺癌连续患者,其中可切除149例(49%),交界可切除157例(51%)。
  • 新辅助治疗为放化疗(32%)、化疗(14%)或两者兼有(54%);总体主要治疗(含术前和术后)为单纯放化疗29例(9%)、单纯化疗14例(5%)、两者兼有263例(86%)。

主要发现

  • 中位随访27个月时,186例(61%)出现复发。
  • 首次复发部位:局部-only 29例(9%),区域-only 19例(6%),远处-only 87例(28%),多部位51例(17%)。
  • 全部患者中位无进展生存期为24个月。

临床怎么用

  • 对于接受新辅助治疗及手术的局限性胰腺癌患者,随访时应关注远处转移,同时局部复发风险仍存在。
  • 新辅助放化疗可能作为改善局部控制的策略之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: More than 70% of patients with localized pancreatic cancer treated with upfront surgery develop disease recurrence. Herein we describe the radiographic patterns and timing of disease recurrence after neoadjuvant therapy and surgery in patients with pancreatic cancer. METHODS: Radiographic patterns of first disease recurrence were examined in patients with localized pancreatic cancer who completed neoadjuvant therapy and surgery. Disease recurrence was classified as local (pancreas, resection bed, or peripancreatic vasculature); regional (peritoneum or abdominal wall); or distant (liver, lung, bone). Progression-free survival was calculated from the date of diagnosis to the date of recurrence. RESULTS: Of 306 consecutive patients who completed neoadjuvant therapy and surgery, 149 (49%) had resectable pancreatic cancer and 157 (51%) had borderline resectable disease. Neoadjuvant therapy consisted of chemoradiation (32%), chemotherapy (14%), or both therapies (54%). Overall, primary therapy (including preoperative and postoperative therapy) consisted of chemoradiation alone in 29 (9%), chemotherapy alone in 14 (5%), and both therapies in 263 (86%) patients. At a median follow-up of 27 months, 186 (61%) of the 306 patients had recurrent pancreatic cancer. Sites of first recurrence were local-only in 29 (9%), regional-only in 19 (6%), distant-only in 87 (28%), and multisite in 51 (17%). The overall median progression-free survival for all patients was 24 months. Neoadjuvant chemoradiation reduced the odds of local-only recurrence (odds ratio: 0.21; 95% confidence interval: 0.06-0.77; P = .02). CONCLUSION: After neoadjuvant therapy and surgery, 9% of patients were found to have local-only recurrence. Treatment sequencing that incorporates neoadjuvant chemoradiation may improve local disease control.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Barnes CA, Aldakkak M, Christians KK, et al. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer. Surgery. 2020. PMID: 32641278. doi:10.1016/j.surg.2020.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。